STOCK TITAN

Kymera Therapeutics, Inc. - KYMR STOCK NEWS

Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.

The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:

  • KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
  • KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
  • KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
  • KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.

Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.

Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.

For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) reported positive interim results from its Phase 1 trial of KT-474, a first-in-class oral IRAK4 degrader, demonstrating a 94% degradation rate. The company initiated dosing for the Multiple Ascending Dose (MAD) portion of the trial and expects Investigational New Drug Applications (IND) for KT-413 and KT-333 in 2H 2021. Following a successful follow-on offering, Kymera now has a pro forma cash position of $647 million to support ongoing development and pipeline expansion. Collaboration revenues rose to $18.5 million while net loss for Q2 2021 was $24.7 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.43%
Tags
-
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced the appointments of Karen Weisbach as Vice President of People and Culture and Jolly Bhatia as Vice President of Quality. Weisbach brings over 15 years of HR experience from bluebird bio, focusing on talent strategies. Bhatia, with 25 years in quality oversight, previously held roles at X4 Pharmaceuticals and Alnylam Pharmaceuticals. These appointments are part of Kymera's effort to strengthen its capabilities in targeted protein degradation and expand its pipeline, which targets immune-inflammatory diseases and various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
management
-
Rhea-AI Summary
Kymera Therapeutics announces preclinical data demonstrating therapeutic potential of STAT3 degraders for the treatment of peripheral T-cell lymphoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.74%
Tags
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) has completed an upsized public offering of 5,468,250 shares at a price of $47.00 per share, raising approximately $257.0 million in gross proceeds. The offering includes an additional 713,250 shares from underwriters' options. The funds will support Kymera's mission to develop novel small molecule protein degraders to tackle difficult disease targets. The company is focused on the treatment of immune-inflammatory diseases and certain cancers through its innovative Pegasus™ platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
-
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced the pricing of its public offering of 4,755,000 shares at $47.00 per share, raising approximately $223.5 million in gross proceeds. All shares are offered by Kymera, with underwriters granted a 30-day option to purchase an additional 713,250 shares. The offering is expected to close on July 6, 2021, pending customary conditions. Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.61%
Tags
-
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced an underwritten public offering of 4,000,000 shares of common stock, with a potential additional 600,000 shares for underwriters. The offering is subject to market conditions and aims to enhance Kymera's ability to advance its protein degradation therapies. Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities are joint book-running managers. A registration statement is filed with the SEC but not yet effective, and the offering will be made only via a prospectus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags
Rhea-AI Summary

Kymera Therapeutics announced positive interim results from the Phase 1 clinical trial of KT-474, showing over 85% target degradation in the Single Ascending Dose (SAD) portion, with a median degradation of 90% at the 300 mg dosage. The degradation was sustained for at least six days without any treatment-related adverse events. The FDA has lifted the partial clinical hold on the Multiple Ascending Dose (MAD) component, allowing Kymera to initiate repeat dosing in July 2021. The study represents a significant step in validating Kymera's targeted protein degradation platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.31%
Tags
-
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) has appointed Elaine Caughey as Chief Business Officer, bringing over 20 years of biotechnology experience. Caughey previously held leadership roles at Cygnal Therapeutics and Biogen. CEO Nello Mainolfi expressed confidence in Caughey's capabilities to drive growth in Kymera’s pipeline, particularly in targeted protein degradation. This transition is crucial as multiple clinical programs are expected to advance this year. Founded in 2016, Kymera focuses on innovative small molecule degraders targeting disease-causing proteins, aiming to develop transformative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
management
-
Rhea-AI Summary

Kymera Therapeutics has announced promising preclinical data for its IRAKIMiD degrader KT-413, showcasing potent anti-tumor efficacy as both a monotherapy and in combination with other anticancer agents for treating MYD88-mutant DLBCL. Presented at the 16th ICML Meeting, KT-413 exhibited superior tumor regression compared to existing therapies in mouse models. The company aims to submit an IND application and start Phase 1 trials in the second half of 2021, marking a significant step forward in targeted therapy for B-cell lymphomas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced the selection of an abstract for oral presentation at the 16th Annual International Conference on Malignant Lymphoma, highlighting new preclinical data for its IRAKIMiD degrader KT-413. The data demonstrate KT-413's potential as an effective monotherapy and in combination with treatments like rituximab or BTK inhibitors against MYD88MT DLBCL. The presentation will cover its differentiated mechanism of action and significant antitumor activity in xenograft models. The session takes place on June 20, 2021, showcasing promising advancements in targeted therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
conferences

FAQ

What is the current stock price of Kymera Therapeutics (KYMR)?

The current stock price of Kymera Therapeutics (KYMR) is $44.23 as of January 23, 2025.

What is the market cap of Kymera Therapeutics (KYMR)?

The market cap of Kymera Therapeutics (KYMR) is approximately 2.8B.

What is Kymera Therapeutics' main focus?

Kymera Therapeutics focuses on developing treatments for previously untreatable diseases using targeted protein degradation to eliminate disease-causing proteins.

What is the Pegasus platform?

Pegasus is Kymera's proprietary platform that leverages predictive modeling and integrated degradation technologies to target and degrade intractable disease-causing proteins.

What are some key drugs in Kymera's pipeline?

Key drugs include KT-474 (IRAK4 degrader), KT-333 (STAT3 degrader), KT-253 (MDM2 degrader), and KT-621 (STAT6 degrader).

What diseases is Kymera targeting?

Kymera is targeting a range of diseases including immuno-inflammatory conditions, various forms of cancer, and TH2-mediated diseases like asthma.

What recent achievements has Kymera made?

Recent achievements include positive preclinical and clinical data, significant partnerships, and financial backing to support operations into 2027.

How does Kymera's technology differ from conventional therapies?

Kymera's technology degrades disease-causing proteins rather than merely inhibiting them, offering potentially more effective and lasting treatments.

Who are Kymera's partners?

Kymera has partnered with leading pharmaceutical companies such as Sanofi and collaborates with various research institutions.

Where is Kymera Therapeutics headquartered?

Kymera Therapeutics is headquartered in Watertown, Massachusetts.

How is Kymera funded?

Kymera has over $745 million in cash reserves, supporting operations and research efforts through various financial backings and a recent equity offering.

Where can I find more information about Kymera?

More information can be found on Kymera's website (www.kymeratx.com) and their official social media profiles on X (formerly Twitter) and LinkedIn.
Kymera Therapeutics, Inc.

Nasdaq:KYMR

KYMR Rankings

KYMR Stock Data

2.79B
63.88M
1.27%
108.2%
13.58%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WATERTOWN